Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation
Peter B. Sick, MD*,*,
Gerhard Schuler, MD ,
Karl Eugen Hauptmann, MD ,
Eberhard Grube, MD, FACC ,
Steve Yakubov, MD, FACC||,
Zoltan G. Turi, MD, FACC¶,
Gregory Mishkel, MD, FACC#,
Steve Almany, MD, FACC** and
David R. Holmes, MD, FACC
* Krankenhaus der Barmherzigen Brüder, Regensburg, Germany
University of Leipzig, Heart Center GmbH, Leipzig, Germany
Krankenhaus der Barmherzigen Brüder, Trier, Germany
Heart Center Siegburg, Siegburg, Germany
|| Midwest Cardiology Research Foundation, Riverside Methodist Hospital, Columbus, Ohio
¶ Cooper Hospital, Camden, New Jersey
# Prairie Education and Research, Springfield, Illinois
** William Beaumont Hospital, Cardiology Center, Royal Oak, Michigan
 Mayo Clinic, St. Marys Hospital, Rochester, Minnesota.

View larger version (97K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Six-Month TEE Control With a Well-Positioned WATCHMAN Device in the LAA
Little color flow is seen behind the device, and no flow around the margins. LAA = left atrial appendage; TEE = transesophageal echocardiography
|
|

View larger version (125K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Anatomical View of the WATCHMAN Device in the LAA in a Patient Who Died From Aortic Dissection
This patient died 9 months after implantation. Stable position and endothelialization of the device were confirmed. LAA = left atrial appendage. Reproduced with permission from K. E. Hauptmann, Trier, Germany.
|
|
|